Log in with your email address username.


[Department of Error] Department of Error

Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016; 388: 2763–74—In this Article, in the Results section, the % of primary non-responders switching to certolizumab pegol who became responders 12 weeks later (week 24) by achieving a DAS28-ESR of 3·2 or less or a DAS28-ESR reduction from week 12 of 1·2 or higher should have read 33 (58%) of 57.